Skin and oral lesions associated to imatinib mesylate therapy.
BACKGROUND
Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects.


CONCLUSIONS
Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph+ in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.
Basso
Fernanda Gonçalves
FG
Hematology and Blood Transfusion Center-University of Campinas, UNICAMP, Campinas, Brazil.
Boer
Camila Cominato
CC
Corrêa
Maria Elvira Pizzigatti
ME
Torrezan
Marcia
M
Cintra
Maria Letícia
ML
de Magalhães
Marina H C Gallottini
MH
da Silva Santos
Paulo
P
de Souza
Cármino Antônio
CA
D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D019226:Oral Ulcer / Q000139:chemically induced* / Q000473:pathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D011743:Pyrimidines / Q000008:administration & dosage / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate